Positive News SentimentPositive NewsNASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $39.57 -1.08 (-2.66%) Closing price 05/29/2026 04:00 PM EasternExtended Trading$39.20 -0.37 (-0.93%) As of 05/29/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enliven Therapeutics Stock (NASDAQ:ELVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enliven Therapeutics alerts:Sign Up Key Stats Today's Range$39.02▼$40.9450-Day Range$28.96▼$48.1152-Week Range$14.78▼$48.53Volume747,896 shsAverage Volume589,135 shsMarket Capitalization$2.41 billionP/E RatioN/ADividend YieldN/APrice Target$58.40Consensus RatingModerate Buy Company Overview Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors. The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications. Enliven applies structure-guided drug design and advanced screening technologies to optimize potency, selectivity and oral bioavailability of its lead compounds. Preclinical studies have demonstrated proof-of-concept in multiple tumor models, supporting planned clinical investigations aimed at overcoming resistance mechanisms that limit the efficacy of conventional therapies. Headquartered in the greater Boston area, Enliven Therapeutics operates in a hub of biopharmaceutical innovation and maintains strategic collaborations with academic institutions and contract research organizations. The company’s management team brings together seasoned executives and scientists with extensive experience in oncology drug discovery and clinical development. Through its focused R&D strategy, Enliven seeks to advance novel precision therapies that address critical unmet needs in cancer treatment. AI Generated. May Contain Errors. Read More Enliven Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreELVN MarketRank™: Enliven Therapeutics scored higher than 74% of companies evaluated by MarketBeat, and ranked 211th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEnliven Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEnliven Therapeutics has a consensus price target of $58.40, representing about 47.6% upside from its current price of $39.57.Amount of Analyst CoverageEnliven Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Enliven Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.59) to ($1.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -23.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -23.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.35% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 8.05.Change versus previous monthShort interest in Enliven Therapeutics has recently decreased by 2.87%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentEnliven Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enliven Therapeutics this week, compared to 3 articles on an average week.Search Interest5 people have searched for ELVN on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows1 people have added Enliven Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,800.00 in company stock.Percentage Held by Insiders25.90% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELVN Stock News HeadlinesEnliven Therapeutics to Present at Upcoming Investor ConferencesMay 21, 2026 | prnewswire.comWhy This Biotech Fund Added $7 Million to an Oncology Stock Up 120%May 14, 2026 | fool.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 30 at 1:00 AM | Profits Run (Ad)Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CMLMay 12, 2026 | prnewswire.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 7, 2026 | prnewswire.comEnliven Therapeutics Inc.April 29, 2026 | barrons.comEnliven Therapeutics (ELVN) price target increased by 11.14% to 52.02April 28, 2026 | msn.comEnliven Therapeutics (ELVN) Up 194% This Year on Strong CML MarketApril 17, 2026 | finance.yahoo.comSee More Headlines ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $15.40 at the start of the year. Since then, ELVN stock has increased by 156.9% and is now trading at $39.57. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. When did Enliven Therapeutics IPO? Enliven Therapeutics (ELVN) raised $80 million in an IPO on Thursday, March 12th 2020. The company issued 4,700,000 shares at a price of $16.00-$18.00 per share. Who are Enliven Therapeutics' major shareholders? Top institutional investors of Enliven Therapeutics include Commodore Capital LP (5.38%), Pictet Asset Management Holding SA (1.53%), Rock Springs Capital Management LP (1.36%) and Siren L.L.C. (1.23%). Insiders that own company stock include Samuel Kintz, 5Am Partners Vi, Llc, Joseph P Lyssikatos, Rishi Gupta, Anish Patel, Benjamin Hohl, Richard A Heyman and Rahul D Ballal. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enliven Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings5/07/2026Today5/30/2026Jefferies Global Healthcare Conference 20266/04/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ELVN's financial health is in the Green zone, according to TradeSmith. ELVN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELVN CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees50Year Founded2019Price Target and Rating Average Price Target for Enliven Therapeutics$58.40 High Price Target$80.00 Low Price Target$45.00 Potential Upside/Downside+47.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.69 million Net MarginsN/A Pretax MarginN/A Return on Equity-21.04% Return on Assets-20.41% Debt Debt-to-Equity RatioN/A Current Ratio40.32 Quick Ratio40.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.44 per share Price / Book5.32Miscellaneous Outstanding Shares60,905,000Free Float45,131,000Market Cap$2.41 billion OptionableOptionable Beta0.32 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ELVN) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMusk lights fire under Swiss chipmaker?While investors chase the SpaceX IPO, one little-known Swiss chipmaker - 148 times smaller than NVIDIA - has q...Brownstone Research | SponsoredTrump’s real warA 29-page National Security Strategy document - what analyst Porter Stansberry calls the 'Donroe Doctrine' - c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
